The potential of nucleolin as a therapeutic target is supported by its expression on the surface of the cells of tumors of diverse histopathological origins, such as hepatocellular carcinoma [65], neuroblastoma [66], gastric [67], and colorectal carcinomas [68], besides pulmonary carcinomas, as herein demonstrated. The gene discussed is NUCLEOLIN; the disease is neuroblastoma.